Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst (Nasdaq:BCRX) announced inducement restricted stock unit grants to six newly hired employees covering an aggregate of 65,850 RSUs, granted as of March 2, 2026 under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date and are subject to the company’s Inducement Equity Incentive Plan and individual RSU agreements.
BioCryst (Nasdaq: BCRX) reported full year 2025 results and a business update on Feb 26, 2026. ORLADEYO net revenue was $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO). The company achieved record GAAP and non-GAAP operating profit, completed the Astria acquisition, and received FDA approval for ORLADEYO pellets for ages 2 to <12.
BioCryst maintained 2026 ORLADEYO revenue guidance of $625–$645 million and full year total revenue guidance of $635–$660 million.
BioCryst (Nasdaq: BCRX) will present at the T.D. Cowen 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026 at 9:10 a.m. ET.
According to the company, a live audio webcast and replay will be available in the Investors & Media section of BioCryst's website at www.biocryst.com.
BioCryst (NASDAQ:BCRX) will present nine HAE abstracts at the 2026 AAAAI Annual Meeting (Feb 27–Mar 2, 2026) including six on ORLADEYO (berotralstat) and three on navenibart.
Key data include pediatric interim APeX-P results in children 2 to <12 years and a late‑breaking ALPHA‑SOLAR interim showing sustained attack suppression with navenibart every 3 or 6 months.
BioCryst (Nasdaq: BCRX) will report fourth quarter 2025 financial results on Thursday, February 26, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Live domestic and international dial‑in numbers are provided, and a webcast replay will be available in the investors section of the company website.
BioCryst (Nasdaq: BCRX) announced inducement equity grants for 24 newly hired employees, comprising 251,150 stock options and 368,550 restricted stock units (RSUs) granted as of February 2, 2026, under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $6.63 equal to the closing price on the grant date, vest in four equal annual installments beginning one year from grant, and each option has a 10-year term. Grants are subject to the Inducement Equity Incentive Plan and applicable award agreements.
BioCryst (Nasdaq: BCRX) completed its acquisition of Astria Therapeutics on Jan 23, 2026 for an implied value of approximately $700 million (net of Astria cash). The deal adds navenibart, a Phase 3 long‑acting plasma kallikrein inhibitor with potential every‑three and every‑six month dosing, to BioCryst’s hereditary angioedema (HAE) franchise alongside the oral therapy ORLADEYO. BioCryst financed the cash portion using on‑hand cash and approximately $396.6 million drawn from a Blackstone‑managed financing facility, and issued about 37.3 million shares to Astria equity holders. Leadership additions from Astria join BioCryst’s board and technical ranks to support development and commercialization.
BioCryst (Nasdaq: BCRX) reported preliminary, unaudited ORLADEYO net revenue of $601 million for full year 2025, up 37% y-o-y and above prior guidance of $590M–$600M. Excluding European ORLADEYO, 2025 net revenue was $563 million (+43% comparable). Q4 2025 ORLADEYO revenue was $151 million (+22% y-o-y; +36% comparable). The company projects 2026 ORLADEYO revenue $625M–$645M, total revenue $635M–$660M, and non-GAAP operating expenses $380M–$390M (or $450M–$470M including the expected Astria acquisition). Cash and investments totaled $338 million at December 31, 2025.
BioCryst (Nasdaq: BCRX) announced that its compensation committee granted a newly hired employee 18,300 restricted stock units (RSUs) as inducement equity under Nasdaq Listing Rule 5635(c)(4).
The RSUs were granted effective January 2, 2026, vest in four equal annual installments beginning on the one-year anniversary of the grant date, and are subject to the recipient’s continued service and the terms of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement.
BioCryst (Nasdaq: BCRX) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 1:30 p.m. ET.
A live audio webcast and replay will be available in the Investors & Media section of BioCryst’s website at www.biocryst.com.